Meta-fluorobenzylguanidine is named as an intervention in 2 current clinical trials in our USA register. 1 is recruiting patients now. The most common phase is Phase 2. The lead sponsor is Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC). The most-studied condition is Heart Failure.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
18F-mFBG Imaging for Myocardial Sympathetic Innervation
NCT06965621 · ClinicalTrials.gov ↗ · Heart Failure, Ischemic Cardiomyopathy, ICD Patients
|
Phase 2 | Recruiting | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | USA |
|
Open-Label Study of 18F-mFBG for Imaging Myocardial Sympathetic Innervation
NCT04535193 · ClinicalTrials.gov ↗ · Cardiovascular Diseases
|
Phase 1/2 | Active, closed | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our USA register name Meta-fluorobenzylguanidine (also registered as 18F-metaFluorobenzylguanidine) as a drug or biological intervention, as of the registry sync on 29 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Meta-fluorobenzylguanidine works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Meta-fluorobenzylguanidine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Meta-fluorobenzylguanidine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 29 Sep 2026.